GlassScriptPhysician profile
Kenneth M Faile
NPI 1750354858
$5,115.56
in general payments reported to CMS, 2019-2025
42 companies · $883 in 2025
The $883 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $928 · 2021: $512 · 2022: $701 · 2023: $1,007 · 2024: $815 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,662 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,662.20 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,514.78 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $647.11 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $340.44 | 2019-2025 | Otezla, Repatha, Otezla |
| Astellas Pharma US INC | $323.65 | 2019-2021 | |
| Novo Nordisk INC | $305.99 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $298.91 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $237.16 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $168.39 | 2020-2024 | Xifaxan, Trulance |
| Abbott Laboratories | $148.35 | 2021-2025 | Freestyle Libre 3 |
| Allergan, INC. | $145.29 | 2020 | |
| Sanofi-Aventis U.S. LLC | $116.56 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $92.18 | 2021-2024 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $71.15 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $59.51 | 2023-2024 | Gvoke Hypopen |
| Shield Therapeutics INC | $56.08 | 2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.92 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $44.92 | 2023 | Xarelto |
| Horizon Therapeutics Plc | $37.78 | 2020-2023 | Krystexxa |
| Idorsia Pharmaceuticals US INC | $36.83 | 2022-2023 | Quviviq |
| Axsome Therapeutics, INC. | $28.67 | 2025 | Auvelity |
| Daiichi Sankyo INC. | $28.16 | 2023 | Injectafer |
| Glaxosmithkline, LLC. | $26.25 | 2019-2023 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $25.99 | 2019-2023 | |
| Scilex Pharmaceuticals INC. | $24.14 | 2024 | |
| Stryker Corporation | $23.97 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Esperion Therapeutics, INC. | $20.41 | 2025 | Nexletol |
| Antares Pharma, INC. | $19.37 | 2025 | Xyosted |
| Boston Scientific Corporation | $19.27 | 2024 | Wavewriter Alpha Prime 16 |
| Dynavax Technologies Corporation | $18.33 | 2025 | Heplisav-B |
| Otsuka America Pharmaceutical, INC. | $18.20 | 2022 | |
| Ardelyx, INC. | $17.46 | 2025 | Ibsrela |
| Actelion Pharmaceuticals US, INC. | $16.90 | 2024 | Uptravi, Opsumit |
| Corcept Therapeutics | $15.39 | 2025 | Korlym |
| Edwards Lifesciences Corporation | $14.87 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Eisai INC. | $14.42 | 2021 | |
| Exact Sciences Corporation | $14.33 | 2025 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $14.25 | 2020 | |
| Phathom Pharmaceuticals, INC. | $14.17 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $13.66 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.14 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.03 | 2020 | |
| Cvrx, INC. | $11.18 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Faile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.